for people ages 12 years and up (full criteria)
at Orange, California and other locations
study started
estimated completion



The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence.

Official Title

A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)


The main purpose of this study is to compare the efficacy, as measured by recurrence-free survival (RFS) by blinded independent central review (BICR), of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA (lymph node [LN] metastasis > 1 mm), Stage IIIB/C/D, or Stage IV (American Joint Committee on Cancer [AJCC] 8th edition) cutaneous melanoma with no evidence of disease (NED) who are at high risk for recurrence.


Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin), CD122-Biased Agonist, CD122-Biased Cytokine, IL-2 Receptor Agonist, NKTR-214, Bempegaldesleukin, IL-2, Immunotherapy, BEMPEG, Nivolumab, Opdivo®, NIVO, Adjuvant, Skin Cancer, Resectable Melanoma, High Risk of Recurrence Melanoma, Post Resection, Checkpoint Inhibitor, Recurrence


You can join if…

Open to people ages 12 years and up

  • Male or female patients, age 12 years or older at the time of signing the informed consent form (age 18 years or older where local regulations, countries, and/or institutional policies do not allow for patients < 18 years of age (adolescents) to participate). In regions where adolescents are not allowed to participate in the study due to age restrictions, enrolled patients must be ≥ 18 years of age.
  • Histologically confirmed Stage IIIA (LN metastasis > 1 mm), IIIB/C/D, or IV (M1a/b/c/d) cutaneous melanoma by AJCC (8th edition) at study entry that has been completely surgically resected within 12 weeks prior to randomization.
  • Tumor tissue available from biopsy or resected disease must be provided to central laboratory for PD-L1 status analysis. Must have PD-L1 expression classification for stratification purposes.
  • Disease-free status documented by a complete physical examination and imaging studies within 28 days prior to randomization.

You CAN'T join if...

  • History of ocular/uveal melanoma or mucosal melanoma.
  • Active, known or suspected autoimmune disease. Patients with Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  • Conditions requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  • Prior therapy for melanoma except surgery for the melanoma lesion(s) and/or adjuvant radiation therapy for central nervous system lesions.
  • Prior therapy with interferon, talimogene laherparepvec (Imylgic®), interleukin-2 (IL-2) directed therapy, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte-associated protein 4 antibody (including ipilimumab or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways).
  • Prior malignancy active within the previous 3 years except for locally potentially curable cancers that have been apparently cured.


  • University of California Irvine
    Orange California 92868 United States
  • Hematology Oncology Medical Group of Orange County, Inc.
    Orange California 92868 United States
  • Kaiser Foundation Hospital, Inpatient Pharmacy
    Anaheim California 92805 United States
  • St. Joseph Heritage Healthcare
    Fullerton California 92835 United States
  • Utah Cancer Specialists (Salt Lake City)
    Salt Lake City Utah 90603 United States
  • Kaiser Permanente
    Riverside California 92505 United States
  • Southern California Permanente Medical Group
    Riverside California 92505 United States


in progress, not accepting new patients
Start Date
Completion Date
Nektar Therapeutics
Phase 3 research study
Study Type
At least 775 people participating
Last Updated